This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nived, O Articles by Olsson, H Search for Related Content PubMed PubMed Citation Articles by Nived, O Articles by Olsson, H Social Bookmarking                   What's this?

Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden

Department of Rheumatology, University Hospital, S 221 85 Lund, Sweden Ola.Nived{at}reum.lu.se

A Bengtsson

A Jönsen

G Sturfelt

Department of Rheumatology, University Hospital, Lund, Sweden

H Olsson

Department of Oncology, University Hospital, Lund, Sweden

The objective of this study was to identify all malignancies in an inception cohort of SLE patients in southern Sweden and compare with the observed frequencies and spectrum of malignancies in the general population. All adult incidence cases of SLE in a defined population during the period 1981–1996 were retrieved from a prospective database and the cases were followed to endpoint or through 1998. The SLE cohort registry was aggregated with the National Cancer Registry to identify all malignancies by date, type and outcome. Standardized morbidity rates (SMR) were calculated based on the sex-and age-matched general population of the region.

Sixteen malignancies occurred in 13 patients out of a total of 116 SLE patients observed for 1086 patient-years. The SMR for all cancers detected was 2.24 (confidence interval 0.6–5.7) for males and 1.02 (confidence interval 0.4–2.1) for females and thus indicative of no general increase in malignancies. However, the SMR for non-Hodgkin lymphoma was 11.63 (confidence interval 1.4–42.0), for pulmonary cancer 5.55 (confidence interval 0.7–20.1) and prostatic cancer 6.41 (confidence interval 1.3–18.7) all significantly increased. The increase in prostatic carcinoma disappeared when only cases occurring after a latency period of 3 y after SLE diagnosis were included.

In this comprehensive inception cohort of SLE no increase in relative risk of malignancy overall was found, but the frequencies of non-Hodgkin lymphoma and pulmonary cancer were increased, possibly also the frequency of prostatic carcinoma.

Key Words: systemic lupus erythematosus • malignancy • epidemiology

Lupus, Vol. 10, No. 7, 500-504 (2001)
DOI: 10.1191/096120301678416079


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M Gayed, S Bernatsky, R Ramsey-Goldman, A. Clarke, and C Gordon Lupus and cancer Lupus, May 1, 2009; 18(6): 479 - 485. [Abstract] [PDF]

				B Lofstrom, C Backlin, C Sundstrom, A Ekbom, and I E Lundberg A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study Ann Rheum Dis, December 1, 2007; 66(12): 1627 - 1632. [Abstract] [Full Text] [PDF]

				B-C Chun and S-C Bae Mortality and cancer incidence in Korean patients with systemic lupus erythematosus: results from the Hanyang Lupus Cohort in Seoul, Korea Lupus, August 1, 2005; 14(8): 635 - 638. [Abstract] [PDF]

				I. Kang, T. Quan, H. Nolasco, S.-H. Park, M. S. Hong, J. Crouch, E. G. Pamer, J. G. Howe, and J. Craft Defective Control of Latent Epstein-Barr Virus Infection in Systemic Lupus Erythematosus J. Immunol., January 15, 2004; 172(2): 1287 - 1294. [Abstract] [Full Text] [PDF]

				O Ragnarsson, G Grondal, and K Steinsson Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus Lupus, September 1, 2003; 12(9): 687 - 691. [Abstract] [PDF]

				A Hrycek, D Kokocinska, J Kosmider, and B Konieczny Letter to the Editor Lupus, February 1, 2003; 12(2): 149 - 152. [PDF]

				M Abu-Shakra, M Ehrenfeld, and Y Shoenfeld Systemic lupus erythematosus and cancer: associated or not? Lupus, March 1, 2002; 11(3): 137 - 144. [Abstract] [PDF]

				G R. Hughes Lupus patients are protected from cancer Lupus, December 1, 2001; 10(12): 833 - 834. [PDF]

				Y Xu and P H Wiernik Systemic lupus erythematosus and B-cell hematologic neoplasm Lupus, December 1, 2001; 10(12): 841 - 850. [Abstract] [PDF]